Compare AMCR & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMCR | GH |
|---|---|---|
| Founded | 1926 | 2011 |
| Country | Switzerland | United States |
| Employees | 50000 | N/A |
| Industry | Miscellaneous manufacturing industries | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.7B | 22.9B |
| IPO Year | 2020 | 2018 |
| Metric | AMCR | GH |
|---|---|---|
| Price | $44.47 | $154.83 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 26 |
| Target Price | $50.98 | ★ $200.76 |
| AVG Volume (30 Days) | ★ 3.7M | 2.1M |
| Earning Date | 11-04-2026 | 11-05-2026 |
| Dividend Yield | ★ 5.84% | N/A |
| EPS Growth | ★ 643.75 | 6.74 |
| EPS | ★ 0.52 | N/A |
| Revenue | ★ $13,640,000,000.00 | $982,021,000.00 |
| Revenue This Year | $2.18 | $39.22 |
| Revenue Next Year | $2.35 | $35.02 |
| P/E Ratio | $86.86 | ★ N/A |
| Revenue Growth | 9.40 | ★ 32.88 |
| 52 Week Low | $8.09 | $74.55 |
| 52 Week High | $50.94 | $191.05 |
| Indicator | AMCR | GH |
|---|---|---|
| Relative Strength Index (RSI) | 47.63 | 40.52 |
| Support Level | $41.19 | $154.16 |
| Resistance Level | $45.22 | $177.55 |
| Average True Range (ATR) | 1.13 | 10.36 |
| MACD | -0.28 | -2.14 |
| Stochastic Oscillator | 11.68 | 36.10 |
Amcor is a global producer of plastic packaging primarily for the fast-moving consumer goods industry. Since the Berry acquisition in 2025, about 60% of earnings are exposed to the flexible packaging business. This is soft disposable plastic for a variety of food, drink, healthcare, and hygiene products. The remainder of earnings are from the Latin and North American rigids business, which includes beverage bottling for the soft drink industry. Operating in more than 35 countries, Amcor has market share in its established regions of North America, Latin America, Europe, and Asia-Pacific. About half of group sales are derived from North America and the remainder is split equally between Western Europe and emerging markets. Australia and New Zealand sales make up less than 5% of group sales.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.